Turnobi

Turnobi is an intravenous formulation of L-citrulline, a non-essential amino acid that serves as a precursor in the nitric oxide (NO) synthesis pathway by being converted to L-arginine and subsequently to NO by nitric oxide synthase. By augmenting endogenous NO production, Turnobi is being developed to improve endothelial function, enhance vasodilation, and modulate microvascular blood flow, particularly in conditions characterized by vaso-occlusion and endothelial dysfunction such as sickle cell disease and acute lung injury. Clinical development has been led through academic–industry collaboration, notably Vanderbilt University and Asklepion Pharmaceuticals, with Phase 2–3 studies evaluating its ability to abort or lessen vaso-occlusive crises in pediatric and young adult patients with sickle cell disease and to prevent or treat acute lung injury in critical care settings.[1][5][7][11][13][17]

Brand names

Turnobi

Other names

L-citrullineL-citrulline intravenousL-citrulline for injection